NF-κB- A potential therapeutic target for inhibition of human cytomegalovirus (Re)activation?

Biological Chemistry

Volumn 383, Issue 10, 2002, Pages 1601-1609

  Prösch, Susanna ^a   Wuttke, Regine ^a   Krüger, Detlev H ^a   Volk, Hans Dieter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

I B super repressor; Immediately early protein 1; Mutagenesis; NF B inhibitors; TNF

Indexed keywords

AMINO ACID; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; ASCORBIC ACID 2 PHOSPHATE; CORTICOSTEROID; CYTOKINE; DEXAMETHASONE; FOSCARNET; GANCICLOVIR; GLUCOCORTICOID; I KAPPA B; IMMEDIATE EARLY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PENTETATE CALCIUM TRISODIUM; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; IE1 PROTEIN, CYTOMEGALOVIRUS; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG TARGETING; ENHANCER REGION; GRANULOCYTE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; INFLAMMATION; MONOCYTE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STEM CELL; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; VIRUS INHIBITION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS TRANSCRIPTION; BINDING SITE; BIOSYNTHESIS; CELL STRAIN HL 60; CONSENSUS SEQUENCE; CYTOMEGALOVIRUS; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYSIOLOGY; PLASMID; VIRUS ACTIVATION;

ALPHAVIRUS; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

BASE SEQUENCE; BINDING SITES; CONSENSUS SEQUENCE; CYTOMEGALOVIRUS; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION, VIRAL; HL-60 CELLS; HUMANS; I-KAPPA B PROTEINS; IMMEDIATE-EARLY PROTEINS; MONOCYTES; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; PHENOTYPE; PLASMIDS; PROMOTER REGIONS (GENETICS); TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS; VIRUS ACTIVATION;

EID: 0036805418     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2002.181     Document Type: Article

References (46)

1. Asadullah, K., Prösch, S., Audring, H., Büttnerova, L., Volk, H.D., Sterry, W., and Döcke, W.D. (1999). A high prevalence of cytomegalovirus antigenemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumor necrosis factor over expression. Br. J. Dermatol. 141, 94-102.
2. Assogba, B.D., Choi, B.H., and Rho, H.M. (2002). Transcriptional activation of the promoter of human cytomegalovirus immediate early gene (CMV-IE) by the hepatitis B viral X protein (HBx) through the NF-κB site. Virus Res. 84, 171-179
3. Baldwin, A.S., Jr. (1996). The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649-683.
4. Barns, P.J. (1998). Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Science 94, 557-572.
5. Bolovan-Fritts, C.A., Mocarski, E.S., and Wiedeman, J.A. (1999). Peripheral blood CD14+ cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 93, 394-398.
6. Carlquist, J.F., Edelman, L., Bennion, D.W., and Anderson, J.L. (1999). Cytomegalovirus induction of interleukin-6 in fibroblasts occurs independently of active infection and involves a G-protein and the transcription factor NF-κB. J. Infect. Dis. 179, 1094-1100.
7. Cherrington, J.M., and Mocarski, E.S. (1989). Human cytomegalovirus ie1 transactivates the α promoter-enhancer via an 18-bp-pair repeat element. J. Virol. 63, 1435-1440.
8. Cheshire, J.L., and Baldwin, A.S. (1997). Synergistic activation of NF-κB by tumor necrosis factor α and γ interferon via enhanced IκBα degradation and de novo IκBβ degradation. Mol. Cell. Biol. 17, 6746-6754.
9. Cinatl Jr., J., Hoffmann F., Cinatl Sr., J., Rabenau, H., Steineker, F., Kabickova, H., Blasko, M., and Doerr, H.W. (1995a). In vitro inhibition of human cytomegalovirus replication by calcium trinatrium diethylenetriaminepentaacetic acid (DTPA). Antiviral Res. 31, 23-34.
10. Cinatl Jr., J., Cinatl Sr., J., Rabenau, H., Gümbel, H.O., Chenot, J.F., Scholz, M., Encke, A., and Doerr, H.W. (1995b). In vitro inhibition of human cytomegalovirus replication in endothelial cells by ascorbic acid 2-phosphate. Antiviral Res. 27, 405-417.
11. Döcke, W.D., Prösch, S., Fietze, E., Kimel, V., Zuckermann, H., Kluge, C., Syrbe, U., Krüger, D.H., von Baehr, R., and Volk, H.D. (1994). Cytomegalovirus reactivation and tumor necrosis factor. Lancet 343, 268-269.
12. Goldberg, A.L., and Rock, K. (2002). Not just research tools - proteasome inhibitors offer therapeutic promise. Nature Med. 8, 338-340.
13. Fishman, J.A., and Rubin, R.H. (1998). Infections in organ-transplant recipients. N. Engl. J. Med. 338, 1741-1751.
14. Fietze, E., Prösch, S., Reinke, P., Stein, J., Döcke, W.D., Staffa, G., Loening, S., Devaux, S., Emmrich, F., von Baehr, R., Krüger, D.H., and Volk, H.D. (1994). Cytomegalovirus infection in transplant recipients: role of tumour necrosis factor. Transplantation 58, 675-680.
15. Greaves, R.F., and Mocarski, E.S. (1998). Defective growth correlates with reduced accumulation of a viral DNA replication protein after low multiplicity infection by a human cytomegalovirus ie1 mutant. J. Virol. 72, 366-379.
16. Grundy, J.E. (1998). Current antiviral therapy fails to prevent the pro-inflammatory effects of cytomegalovirus infection, whilst redering infected cells relatively resistant to immune attack. In: CMV-Related Immunopathology, Monographs in Virology, Vol. 21, M. Scholz, H.F. Rabenau, H.W. Doerr, and J. Cinatl Jr., eds. (Basel, Switzerland: S. Karger), pp. 67-89.
17. Hahn, G., Jores, R., and Mocarski, E.S. (1998). Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc. Natl. Acad. Sci. USA 95, 3937-3942.
18. Hummel, M., Zhang, Z., Yan, S., Deplaen, I., Golia, P., Varghese, T., Thomas, G., and Abecassis, M.I. (2001). Allogenic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: a model for reactivation from latency. J. Virol. 75, 4814-4822.
19. Karin, M. (1999). The beginning of the end: IκB kinase (IKK) and NF-κB activation. J. Biol. Chem. 274, 27339-27342.
20. Kondo, K., and Mocarski, E.S. (1995). Cytomegalovirus latency and latency specific transcription in hematopoietic progenitors. Scand. J. Infect. Dis. (Suppl.) 99, 63-67.
21. Kondo, K., Xu, J., and Mocarski, E.S. (1996). Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc. Natl. Acad. Sci. USA 93, 11137-11142.
22. Kutza, A.S.T., Muhl, E., Hackstein, H., Kirchner, H., and Bein, G. (1998). High incidence of active cytomegalovirus infection among septic patients. Clin. Infect. Dis. 26, 1076-1082.
23. Marchinin, A., Lui, H., and Zhu, H. (2001). Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. J. Virol. 75, 1870-1878.
24. McKay, L.I., and Cidlowski, J.A. (1999). Molecular control of immune/inflammatory response: interactions between nuclear factor-κB and steroid receptor-signaling pathways. Endocrine Rev. 20, 435-459.
25. Meier, J.L., and Stinski, M.F. (1996). Regulation of human cytomegalovirus immediate-early gene expression. Intervirology 39, 331-342.
26. Meier, J.L., and Pruessner, J.A. (2000). The human cytomegalovirus major immediate-early distal enhancer region is required for efficient viral replication and immediate-early gene expression. J. Virol. 74, 1602-1613.
27. Mendelson, M., Monard, S., Sissons, P., and Sinclair, J. (1996). Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J. Gen. Virol. 77, 3099-3102.
28. Mocarski, E.S., Kemble, G.W., Lyle, J.M., and Greaves, R.F. (1996). A deletion mutant in the human cytomegalovirus gene encoding IE1 (491aa) is replication defective due to failure in autoregulation. Proc. Natl. Acad. Sci. USA 93, 11321-11326.
29. Mutimer, D., Mirza, D., Shaw, K., O'Donnell, K., and Elias, E. (1997). Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients. Transplantation 63, 1411-1415.
30. Palombella, V.J., Rando, O.J., Goldberg, A.L., and Maniatis, T. (1994). The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773-785.
31. Prösch, S., Staak, K., Stein, J., Liebenthal, C., Stamminger, T., Volk, H. D., and Krüger, D.H. (1995). Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFα is mediated via induction of NF-κB. Virology 208, 197-206.
32. Prösch, S., Volk, H.D., Reinke, P., Pioch, K., Döcke, W.D., and Krüger, D.H. (1998). Human cytomegalovirus infection in transplant recipients: role of TNFα for reactivation and replication of human cytomegalovirus. In: CMV-Related Immunopathology, Monographs in Virology, Vol. 21, M. Scholz, H.F. Rabenau, H.W. Doerr, and J. Cinatl Jr., eds. (Basel, Switzerland: S. Karger), pp. 29-42.
33. Prösch, S., Wendt, C.E.C., Reinke, P., Priemer, C., Oppert, M., Krüger, D.H., Volk, H.D., and Döcke, W.D. (2000). A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. Virology 272, 357-365.
34. Prösch, S., Heine, A.K., Volk, H.D., and Krüger, D.H. (2001). CAAT/enhancer-binding proteins α and β negatively influence the capacity of tumor necrosis factor α to upregulate the human cytomegalovirus IE1/2 enhancer/promoter by nuclear factor κB during monocyte differentiation. J. Biol. Chem. 276, 40712-40720.
35. Sambucetti, L.C., Cherrington, J.M., Wilkinson, G.W.G., and Mocarski, E.S. (1989). NF-κB activation of the human cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J. 8, 4251-4258.
36. Scholz, M., Doerr, H.W., and Cinatl, J. (2001). Inhibition of cytomegalovirus immediate early gene expression: a therapeutical option? Antiviral Res. 49, 129-145.
37. Sindre, H., Tjoonnfjord, G.E., Rollag, H., Ranneberg-Nilsen, T., Veiby, O.P., Beck, S., Degre, M., and Hestdal, K. (1996). Human cytomegalovirus suppression of and latency in early hematopoietic progenitor cells. Blood 88, 4526-4533.
38. Slobedman, B., and Mocarski, E.S. (1999). Quantitative analysis of latent human cytomegalovirus. J. Virol. 73, 4806-4812.
39. Staak, K., Prösch, S., Döcke, W.D., Krüger, D.H., Volk, H.D., and Reinke, P. (1997). Pentoxifylline promotes replication of cytomegalovirus in vivo and in vitro. Blood 89, 3682-3690.
40. Stamminger, T., Fickenscher, H., and Fleckenstein, B. (1990). The cell type specific induction of the major immediate early enhancer of human cytomegalovirus by cAMP. J. Gen. Virol. 71, 105-113.
41. Stein, J., Volk, H.D., Liebenthal, C., Krüger, D.H., and Prösch, S. (1993). Tumor necrosis factor α stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J. Gen. Virol. 74, 2333-2338.
42. Verma, I.M., and Stevenson, J. (1997). IκB kinase: beginning, not the end. Proc. Natl. Acad. Sci. USA 94, 11758-11760.
43. White, K.L., Slobedman, B., and Mocarski, E.S. (2000). Human cytomegalovirus latency-associated protein pORF94 is dispensable for productive and latent infection. J. Virol. 74, 9333-9337.
44. Yamamoto, Y., and Gaynor, R.B. (2001). Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 107, 135-142.
45. Yurochko, A.D., Mayo, M.W., Poma, E.E., Baldwin, A.S., and Huang, E.S. (1997). Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the pp65 and p105/p50 NF-κB promoters. J. Virol. 71, 4638-4648.
46. Yurochko, A.D., and Huang, E.S. (1999). Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. J. Immunol. 162, 4806-4816.